Aim: Angiotensin-converting enzyme (ACE) inhibition can reduce the body weight of mice maintained on a high-fat diet. The current study examined the effect of the ACE inhibitor, captopril (CAP), on the reversal of diet-induced obesity (DIO), insulin resistance and inflammation in mice. Materials and methods: DIO was produced in C57BL/6J male mice (n ¼ 30) by maintaining animals on a high-fat diet (w/w 21% fat) for 12 weeks. During the subsequent 12-week treatment period, the animals were allowed access to the high-fat diet and either water containing CAP (0.05 mg ml À1 ) or plain tap water (CON, control). Results: From the first week of treatment, food intake and body weight decreased in CAP-treated mice compared with CON mice. Both peripheral insulin sensitivity and hepatic insulin sensitivity were improved in CAP-treated mice compared with CON mice. CAP-treated mice had decreased absolute and relative liver and epididymal fat weights compared with CON mice. CAP-treated mice had higher plasma adiponectin and lower plasma leptin levels than CON mice. Relative to CON mice, CAP-treated mice had reduced adipose and skeletal muscle monocyte chemoattractant protein 1 (MCP-1), adipose interleukin-6 (IL-6), toll-like receptor 4 (TLR4) and uncoupling protein 2 (UCP2) mRNA expressions. Furthermore, CAP-treated mice had increased peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a), long chain acyl-CoA dehydrogenase (LCAD), hormone sensitive lipase (HSL) and decreased lipoprotein lipase (LPL) mRNA expressions in the liver.
Introduction
Obesity is becoming the major epidemic of the 21st century, predominately in developed countries, although it is now recognized globally. Approximately 1.6 billion adults worldwide are overweight, and 400 million fulfil the obesity criteria. 1 Obesity is associated with a number of other diseases, including type-2 diabetes, cardiovascular disease and certain cancers. 2 A common emerging link is chronic systemic inflammation. In lean individuals, non-or anti-inflammatory factors such as interleukin (IL)-10 or IL-13, or insulin-sensitizing factors, are secreted by adipocytes. 3 As individuals become obese, macrophages begin to accumulate within the adipose tissue and lead to local inflammation. As obesity increases several pro-inflammatory factors are produced in the adipose tissue. In fact, the adipose tissue of obese individuals shows a higher expression of pro-inflammatory proteins, including IL-6, tumour necrosis factor-a (TNFa) and monocyte chemoattractant protein-1 (MCP-1), compared with lean individuals. 4, 5 Chronic activation of intracellular pro-inflammatory pathways within insulin target cells can lead to obesity-related insulin resistance. 6 Obesity associated activation of macrophages leads to increased production of pro-inflammatory mediators such as TNFa, IL-1b, and resistin that act on adipocytes to induce an insulin resistant state. 7 Furthermore, negative correlations observed between TNFa and high-density lipoprotein cholesterol, glycosylated haemoglobin and serum insulin concentrations explain why coronary heart disease is more frequent in obese compared with healthy or lean subjects. 8 In addition to high levels of pro-inflammatory cytokines, adipose tissue from obese individuals has been shown to secrete angiotensin-II (ANG-II), the biologically active component of the renin-angiotensin system (RAS). All enzymes required to form the peptide ANG-II are found in adipocytes. 9 High plasma ANG-II levels are associated with human obesity, 10 and evidence suggests that ANG-II contributes to obesity and insulin resistance. 11 Metabolically, ANG-II has been shown to increase both fatty acid (FA) and triglyceride synthesis, 12 while inhibiting lipolysis in adipose and skeletal muscle tissues. 13 ANG-II has also been shown to impair insulin secretion by pancreatic b-cells and reduce insulin sensitivity in peripheral tissues. ANG-II induces nicotinamide adenine dinucleotide phospho hydrogenase (NADPH) oxidase production in pancreatic b-cells, eliciting an increased oxidative stress resulting in b-cell apoptosis. 14 ANG-II was shown to induce an inflammatory response through the activation of nuclear factor-kB (NF-kB) in cardiac tissue. 15 Furthermore, ANG-II increased the expression of inflammatory mediators such as MCP-1 in cultured monocytes 16 and toll-like receptor-4 (TLR4)
in cultured mesangial and vascular smooth-muscle cells. 17, 18 Thus, the evidence suggests that the RAS has an important role in obesity and insulin resistance. Angiotensin-converting enzyme (ACE) inhibitors are widely used as a treatment for primary hypertension. ACE inhibitors inhibit the formation of ANG-II and thereby reduce arterial and venous pressures. 19 The actions of ACE inhibition extend beyond blood pressure regulation and improvements in whole-body insulin activity are reported in numerous insulin-resistant rodent models after ACE treatment. 20, 21 In addition, ACE inhibitors or angiotensinreceptor blockers reduce both body weight and body fat. 22, 23 The ACE inhibitor, captopril (CAP), has been shown to prevent the development of obesity in rodents fed with a high-fat diet, 22, 24 although the mechanisms remain unresolved. It has recently been speculated that the antioxidative and anti-inflammatory properties of CAP may contribute to the improvement in body weight. 25 This study aims to investigate whether ACE inhibition results in weight loss in a diet-induced obesity (DIO) model, in addition to improving insulin resistance and reducing inflammation. To achieve this, obesity-prone C57BL/6J mice were fed a high-fat diet for 12 weeks. The dietary regime was continued for another 12 weeks in the presence of CAP treatment. To determine the effect of CAP treatment in vivo, body weight, ingestive behaviours and body composition were determined. Glucose tolerance and pyruvate challenge tests were performed to assess the effect of CAP treatment on peripheral insulin resistance and hepatic insulin resistance. Furthermore, plasma hormones (leptin and adiponectin), non-esterified FAs (NEFAs) and expression of gene transcripts involved with inflammation (IL-6, MCP-1, TLR4), lipolysis (adipose triglyceride lipase (ATGL), lipoprotein lipase (LPL), hormone-sensitive lipase (HSL)), FA oxidation (adiponectin, long-chain acyl-CoA dehydrogenase (LCAD), carnitine palmitoyl transferase-1 (CPT-1)) and fat storage (FA synthase (FAS)) were assessed in adipose, skeletal muscle and liver tissues.
Materials and methods

Animals
Six-week-old male C57BL/6J mice (n ¼ 30; Monash Animal Services, Clayton, VIC, Australia) were housed in individual plastic cages in the Central Animal House (La Trobe University, Bundoora, VIC, Australia) with a 12-h light/dark cycle and with temperatures maintained at 22±3 1C. The animal procedures were approved by the Animal Ethics Committee of La Trobe University.
During an initial 12-week period, animals were given a semi-synthetic, high-fat diet (21% fat; Speciality Feeds, Glen Forrest, WA, Australia) (see Table 1 ) and water ad libitum. Then the mice were randomly assigned to the control (CON) or CAP-treated groups (n ¼ 15/group), and were continued on those regimens for another 12 weeks. The CON group received water alone, whereas CAP (Sigma-Aldrich, St Louis, MO, USA) was given at 0.05 mg ml À1 for a total of 3.69-6.78 mg kg À1 per day, depending on the amount of fluid consumed on a given day. Generally, hypertensive patients are treated with CAP at a dose of about 50-100 mg per day. 26 Therefore, as an example, a 70-kg man would be treated with CAP at a dose of about 0.7-1.4 mg kg À1 per day. Taking into consideration that the metabolic rate of a mouse is about 10-fold higher compared with that of a human, the dose used in the current study is similar to the recommended CAP dose for treatment of hypertension in humans. Water or CAP -treated water was provided daily, and the high-fat diet was continued throughout treatment ad libitum. Weekly body weight and daily food and fluid intakes were measured throughout the treatment period.
Glucose tolerance test and pyruvate challenge test Glucose tolerance test (GTT) and pyruvate challenge test (PCT) were performed between the 10th and 12th weeks of ; intraperitoneal, 0.1-0.5 ml). Blood samples were collected by direct cardiac puncture into EDTAtreated syringes (20 ml of 0.134 M EDTA solution). Subsequently, the plasma was separated by centrifugation at 13 000 r.p.m. for 15 min, whereas liver, epididymal fat and quadriceps muscle were collected and snap-frozen in liquid nitrogen. All samples were stored at À80 1C until further analysis.
Measurement of plasma adiponectin, leptin and NEFA Plasma adiponectin and leptin concentrations were determined using a Mouse Adiponectin ELISA kit and a Mouse Leptin ELISA kit (Millipore, Billerica, MA, USA), respectively. Absorbance was read at 450 and 520 nm for all assays using an xMark microplate spectrophotometer (Bio-Rad, Philadelphia, PA, USA). Plasma NEFA concentration was measured by an enzymatic method using a NEFA assay kit (Roche Diagnostics, Rotkreuz, ZG, Switzerland).
Analysis of mRNA expression
Total RNA was extracted from B100 mg of adipose, B15 mg of skeletal muscle and B10 mg of liver tissues using the Trireagent (PE Applied Biosystems, Corona, CA, USA). Nanodrop 1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to determine the purity of RNA and the ratio (A 260 /A 280 ) values were close to 2.0. A high-capacity RNA-tocDNA reverse transcriptase kit (PE Applied Biosystems) was used to synthesize cDNA from 2 mg of RNA from adipose and liver tissues and 0.5 mg of RNA from skeletal muscle in a total of 20 ml of reaction volume. Reverse transcription was performed by incubating the samples at 42 1C for 1 h, 99 1C for 5 min, followed by 4 1C for 5 min. Reverse transcription-PCR amplification was performed using 1 ml of cDNA diluted at either 1:10 or 1:20 using gene-specific primer sets (GeneWorks Pty Ltd, Hindmarsh, SA, Australia). The oligonucleotide sequences of the forward (sense) and reverse (antisense) primers used for amplification are as in Table 2 . Each primer set was used at a concentration of 200 nM in a final volume of 14 ml using the Power SYBR Green PCR Master Mix (PE Applied Biosystems). Real-time PCR was performed using the fluorometric thermal cycler (7500 Fast Real-Time PCR System; PE Applied Biosystems) where target expression was normalized to the amount of endogenous control (28S ribosomal RNA for adipose and skeletal muscle tissues and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for liver tissue) relative to CON value, given by DDC T method.
Statistical analysis
Results are reported as the mean±s.e.m. Body weight, food and water intake, glucose tolerance and pyruvate challenge were analysed by two-way, repeated-measures analysis of variance (ANOVA), with group and time as factors, repeated for time, followed by a post hoc least significant difference test (Statistica 7; StatSoft, Tulsa, OK, USA). Final body weight, tissue weights, plasma adiponectin, leptin and NEFA levels, and expression of mRNA were analysed by unpaired Student's t-test. Correlations between epididymal fat and plasma leptin, epididymal fat and plasma adiponectin, and plasma adiponectin and plasma leptin were calculated using Pearson's product-moment correlation (r) (SigmaPlot 9; Systat Software, Chicago, IL, USA). Statistical significance was accepted at Po0.05.
Results
Body weight, body composition and intake of fluid and food After 12 weeks on a high-fat diet, male C57BL/6J mice were randomized to the CON or CAP group. Body weights on randomization did not differ (Figure 1a) . Analysis of body weight data by two-way, repeated-measures ANOVA indicated a significant interaction between group and time (F(12,324) ¼ 30.892, Po0.05). The CON animals continued to gain weight throughout the experiment. However, from the first week of treatment onwards, the CAP-treated mice began to lose weight and by the end of the second week of treatment they were 16% lighter than their pre-treatment weight (Po0.05). After the 12-week treatment period, the CAP-treated mice weighed less than the CON group by 20-30% (Po0.05). As shown in Table 3 , compared with the CON group, the CAP-treated group had decreased absolute and relative liver and epididymal fat weights (Po0.05).
Pre-treatment fluid intake was not different between groups (2.2 ± 0.12 ml per day) (Figure 1b) . Analysis of fluid intake data by two-way, repeated-measures ANOVA indicated a significant interaction between group and time (F(12,324) ¼ 22.164, Po0.05). The fluid intake by the CAPtreated group rapidly increased from the first week until the fifth week of the treatment period compared with that of the CON group, and from the fifth week onwards fluid intake stabilized. Throughout the 12-week treatment period, the fluid intake by the CAP-treated mice was 1.5-to 2.0-fold ACE inhibition, obesity and inflammation SD Premaratna et al Table 2 Gene-specific forward and reverse primer sequences used for reverse transcription-PCR ACE inhibition, obesity and inflammation SD Premaratna et al higher than that of the CON group (CON: 2.4±0.02 ml per day versus CAP: 4.1 ± 0.02 ml per day, Po0.05). Pre-treatment food intake was not different between groups (2.44±0.06 g per day) (Figure 1c) . Analysis of food intake data by two-way, repeated-measures ANOVA indicated a significant interaction between group and time (F(12,324) ¼ 2.4943, Po0.05). The food intake by the CAP-treated mice significantly decreased compared with that of the CON group by the end of the first week, and from the second week onwards it gradually increased. However, from week 1 onwards the food intake by the CAP-treated group was significantly lower than that of the CON group except in weeks 6, 10 and 12. The slight decrease in food intake in both the CON group and the CAP-treated group in week 10 may have occurred as a result of changing the room in which they were housed. The cumulative food intake by the CAP-treated group was less than that of the CON group (CON: 264.19 ± 15.3 g versus CAP: 211.94 ± 6.9 g, Po0.05).
Glucose tolerance test
Analysis of glucose tolerance data by two-way, repeatedmeasures ANOVA indicated a significant interaction between group and time (F(4,108) ¼ 2.4784, Po0.05). The fasted blood glucose levels between the CAP-treated group and the CON group were not different at baseline or at 30 and 60 min after the glucose load (Figure 2a) . However, the blood glucose concentration of the CAP-treated mice was lower than that of the CON group at both 90-and 120-min time points (Po0.05).
Pyruvate challenge test
Analysis of pyruvate challenge data by two-way, repeatedmeasures ANOVA indicated a significant interaction between group and time (F(4,108) ¼ 4.3573, Po0.05). As shown in Figure 2b , there was no difference in the fasted blood glucose levels between the CAP-treated mice and the CON group at baseline or at the 30 min time point after the pyruvate load. However, at 60-, 90-and 120-min time points, the blood glucose concentrations of the CAP-treated group was lower than that of the CON group (Po0.05).
Plasma hormones and metabolites
The plasma adiponectin level of the CAP-treated mice was two-fold higher compared with that of the CON group (CON: 11.09±1.87 mg ml À1 versus CAP: 21.00±2.21 mg ml À1 , t 22df ¼ 5.20373, Po0.05) (Figure 3a) . The plasma leptin level of the CAP-treated group was approximately half that of the CON animals (CON: 30.57±1.4 ng ml À1 versus CAP: 14.63±
ng ml
À1
, t 23df ¼ À5.40193, Po0.05) (Figure 3b) . The plasma NEFA level was not different between these groups (Figure 3c ).
There was a very high correlation between plasma leptin concentration and epididymal fat mass (Figure 4a , r ¼ 0.924, Po0.05). The correlation between plasma adiponectin ACE inhibition, obesity and inflammation SD Premaratna et al concentration and epididymal fat mass was not significant as shown in Figure 4b . However, there was a high correlation between plasma leptin and plasma adiponectin (Figure 4c , r ¼ À0.499, Po0.05).
Adipose tissue mRNA As shown in Figure 5a , expression of mRNA for leptin (t 25df ¼ À3.28455, Po0.05), IL-6 (t 25df ¼ 3.98036, Po0.05), MCP-1 (t 25df ¼ À2.99411, Po0.05), uncoupling protein-2 (UCP2) (t 25df ¼ À3.70202, Po0.05) and TLR4 (t 25df ¼ À2.95177, Po0.05) decreased in the adipose tissue of CAPtreated mice compared with that of the CON group. There was no difference in the expression of mRNA for adiponectin, peroxisome proliferator-activated receptor-g (PPARg), PPARg coactivator-1a (PGC-1a), D9 desaturase/stearoyl-Co-A desaturase (D9D/SCD1) or HSL between these groups.
Skeletal muscle tissue mRNA
As shown in Figure 5b , expression of mRNA for MCP-1 (t 19df ¼ À2.29929, Po0.05) was decreased in the CAP-treated mice compared with that of the CON group. The expression of mRNA for IL-6 and D9D/SCD1 were not different between groups.
Liver tissue mRNA As shown in Figure 5c , expression of mRNA for PGC-1a (t 27df ¼ À4.05915, Po0.05), HSL (t 27df ¼ À3.08167, Po0.05) and LCAD (t 26df ¼ À4.05680, Po0.05) increased, whereas for LPL (t 26df ¼ 2.52893, Po0.05) it was decreased in the CAPtreated group compared with that of the CON group. The expression of mRNA for CPT-1, FAS and ATGL were not different between groups.
Discussion
The current study showed the effectiveness of CAP, an ACE inhibitor, to reduce DIO, improve insulin sensitivity and reduce adipose tissue inflammation in C57BL/6J mice. Previously, it was reported that CAP is capable of reducing DIO in a short-term study of rats. 24 The current study extended those findings: CAP reduced DIO in mice and this weight loss was maintained throughout the 12-week treatment period. In addition to this weight loss, CAP treatment improved peripheral insulin sensitivity as indicated by GTT and decreased the rate of gluconeogenesis in the liver as indicated by the PCT. A more detailed analysis of adipose and skeletal muscle tissues showed that CAP treatment decreased the expression of mRNA for inflammatory factors, including MCP-1, IL-6 and TLR4. Furthermore, in liver tissue, CAP treatment modified the expression of genes involved in lipid metabolism; expression of mRNA for PGC-1a, HSL and ACE inhibition, obesity and inflammation SD Premaratna et al LCAD was increased whereas expression of mRNA for LPL was decreased. Twelve weeks of high-fat diet resulted in DIO in C57BL/6J mice and subsequent treatment with CAP resulted in rapid weight loss. At the end of the second week, the body weight of the CAP-treated mice was 16% less than that of the mice maintained on the high-fat diet alone. This weight loss was maintained for 12 weeks and was about 3-to 4-fold greater than the weight loss recorded in Long-Evans rats treated with CAP at a dose of 40 mg kg À1 per day for 1-2 weeks. 24 To the best of our knowledge CAP has not been effective in reducing body weight in humans. However, in a clinical trial the ACE inhibitor enalapril reduced weight in patients with hypertension. 27 The marked reduction in body weight we observed appears to be predominantly because of reduction of body fat. Reduction of body fat may have occurred as a result of increased lipolysis in major fat depots such as adipose tissue and liver, with subsequent increase in FA oxidation. HSL is a lipase responsible for hydrolysis of intracellular triacylglycerol and diacylglycerol, and is one of the key molecules controlling lipolysis. 28 In the current study, expression of mRNA for HSL in liver tissue was increased in the CAP-treated group compared with that of the CON group, which suggests that there may have been increased lipolysis in the liver tissue. The increased lipolysis in the liver tissue may, in return, have led to decreased absolute and relative liver weights observed in this group. Furthermore, in the liver expression of mRNA for PGC-1a and LCAD was also increased in the CAP-treated mice compared with that of the CON group. PGC-1a is involved with induction of fat metabolism and has also been implicated in mitochondrial and peroxisomal biogenesis, 29 whereas LCAD is responsible for FA oxidation in both mitochondria and peroxisomes. 30 Thus, the results suggest that CAP treatment increases several other liver enzymes that increase FA oxidation and that can contribute to the decreased body fat. Furthermore, these enzymes have been previously shown to be increased in ACE-knockout mice, which have decreased production of ANG-II and reduced body fat. ACE inhibition, obesity and inflammation SD Premaratna et al
Low body fat levels in the CAP-treated mice were reflected in the decrease in plasma leptin, and the increase in plasma adiponectin, adipokines correlated with body fat. 22, 32 Adiponectin increases FA metabolism in muscle and liver 33, 34 through activation of AMP-activated protein kinase. 35 Subsequently, activation of AMP-activated protein kinase leads to increased FA oxidation, reduced FA synthesis and reduced body fat, which ultimately leads to reduction of body weight. 22 Interestingly, even though there was an increase in the plasma adiponectin level in the CAP-treated group, expression of mRNA for adiponectin was not different between these groups. This indicates that the effect of CAP on plasma adiponectin is more related to post-transcriptional modification or to changes in adiponectin degradation. 36 By contrast, certain studies have shown that blockade of the RAS stimulates adiponectin production in rodents. 37, 38 However, the molecular mechanisms by which RAS inhibition stimulates adiponectin production remain unclear. 39 Inhibition of reactive oxygen species generation by NADPH oxidase in adipose tissue may be a mechanism for the increased adiponectin level observed when treated with RAS antagonists. 37 Another possible mechanism by which angiotensin-receptor blockers may improve adiponectin production is by activating PPARg. However, this seems to be true for only some of the angiotensin-receptor blockers that is, irbesartan and telmisartan. 40 Finally, blocking angiotensin type-1 (AT1) receptors increases the activation of angiotensin type-2 (AT2) receptors and may increase adiponectin production. 40 The reduction in food intake observed in the CAP-treated group is consistent with a previous report, 24 and may be one of the causes of the body weight reduction observed in the CAP-treated animals. On the other hand, it is conceivable that the primary influence of CAP is to increase FA oxidation, and the increased availability of energy produced by the burning of fat then influences the mechanisms controlling food intake. The observed decrease in food intake, therefore, may reflect increased energy produced from FA oxidation, which allows reduced ingestion of food. Furthermore, even though there is a gradual increase in the food intake by the CAP-treated animals over time, their body weights remained lower than the CON group, which further suggests that the weight loss observed in the CAP-treated animals may have occurred due to decreased body fat as a result of FA oxidation. Among previous studies that reported decreased body weight/body fat with an antagonist of the RAS, several reported decreased food intake 41,42 whereas others did not. 22, 43 Therefore, the role of decreased food intake is still to be resolved. Fluid intake by the CAP-treated mice was significantly increased, which is consistent with previous studies. 22, 31 This could be because of increased bradykinin levels 44 or increased ANG-II synthesis in the brain. 45 As the fluid intake by the CAP-treated mice is elevated compared with that of the CON group, the reduction in food intake by the CAPtreated mice is not due to a general suppression of behaviour by CAP. Furthermore, ANG-II does not affect ghrelin-induced food intake, 46 although it causes a large increase in fluid intake. 45 Therefore, the decreased food intake by the CAPtreated mice is not due to increased fluid intake. Previously, CAP has been shown to improve glucose tolerance in various animal models. 22, 24 GTT results showed that CAP treatment improved the impaired glucose tolerance in mice with DIO. This observation provides evidence of improved insulin-dependent glucose clearance, 47 and, importantly, it occurred in animals that did not have a reduced NEFA level. Improved glucose tolerance may occur as a result of several mechanisms. It may have occurred as a result of reduced hepatic glucose production owing to increased circulating adiponectin levels, and/or because of increased glucose uptake and FA oxidation in skeletal muscles. 48 Hepatic insulin resistance is a principal cause of type-2 diabetes. 49, 50 In insulin resistance, hepatic gluconeogenesis is increased. 51 In order to determine the rate of gluconeogenesis in the liver, PCT was performed. 52 The results of the PCT showed that the CAP-treated mice had a decreased rate of hepatic gluconeogenesis compared with that of the CON group. Thus, the GTT results show that CAP improves insulin-dependent glucose clearance, which indicates improved peripheral insulin sensitivity, and the PCT results show that CAP specifically inhibits hepatic gluconeogenesis, which indicates improved hepatic insulin sensitivity. IL-6 causes hepatic insulin resistance by inhibiting insulin receptor signalling and increasing insulin receptor substrate-1 degradation. 53 TLR4 has been shown to activate intracellular inflammatory pathways involving NF-kB, which regulates hepatic insulin resistance, 54 and UCP2, which has been shown to be a negative regulator of insulin secretion. 55 The current study shows a decrease in expression of mRNA for the IL-6, TLR4 and UCP2 genes in the adipose tissues of the CAP-treated mice compared with that of the CON group. Thus, the present results show that CAP can improve insulin sensitivity, but further work is required to identify the mechanisms involved. Fat accumulation leads to increased circulating levels of several markers of inflammation known as inflammatory cytokines. 56 The results of the current study showed a marked reduction in the expression of mRNA for proinflammatory cytokines such as MCP-1, IL-6 and leptin in peripheral tissues after CAP treatment. The increased inflammatory process that occurs with obesity leads to an increased infiltration of macrophages into adipose tissue. MCP-1 is a chemoattractant, which has a major role in the recruitment of monocytes/macrophages into adipose tissue. Obesity correlates with a marked increase in both circulating and adipose tissue MCP-1 levels. 57 Furthermore, MCP-1-knockout mice fed a high-fat diet have a low macrophage and inflammatory gene profile in adipose tissue and are less insulin-resistant and have had reduced hepatic steatosis compared with wild-type mice. 58 Therefore, the current study suggests that CAP could reduce the inflammatory response and improve insulin sensitivity by reducing the ACE inhibition, obesity and inflammation SD Premaratna et al expression of mRNA for MCP-1 in both adipose and skeletal muscle tissues. In summary, CAP reduced DIO in mice, improved glucose tolerance and reduced the expression of mRNA for inflammatory markers. The decreased body weight is associated with decreased fat accumulation in adipose and liver tissues. Increased adiponectin levels and reduced expression of mRNA for UCP2 may have contributed to the improvement in insulin sensitivity. Reduction in the expression of mRNA for MCP-1, IL-6 and TLR4 may have led to a reduction in the inflammatory response. Therefore, the results of the current study suggest that CAP may be a promising tool to reverse DIO, improve insulin sensitivity and reduce inflammation.
